Inserm Transfert and GSK sign a worldwide license agreement on novel immune checkpoint modulators for the treatment of cancer
December 11, 2013, Paris (France) – Inserm Transfert and GlaxoSmithKline (GSK) have signed an exclusive worldwide license agreement to develop therapeutic antibodies targeting an immune checkpoint molecule for the emerging area of immuno-oncology.
The deal is based upon Inserm research developed by Professor Daniel Olive and his team at CRCMInstitut Paoli-Calmettes (IPC) that aims to investigate the function of immune-checkpoint molecules such as ICOS (Inducible T-cell COStimulator). This protein along with other co-stimulatory proteins plays an important role in immune responses and could be a potential major target for both cancer and other therapeutic strategies. It follows the recent trend in cancer research with significant clinical results in this field as highlighted at ASCO’13 such as antibodies against PD1/PDL1 and CTLA4.
Under the terms of the agreement, Inserm Transfert has granted GSK exclusive worldwide rights to develop and commercialise the monoclonal antibodies, which modulate ICOS on the surface of T cells and enhances anti-tumour immune responses. In addition to an undisclosed upfront fee, Inserm Transfert will receive milestones from GSK linked to the development of the product(s), as well as royalties on sales from any product that is successfully commercialised from the collaboration